1. A Phase II Pilot Study to Evaluate Use of Intravenous Lidocaine for Opioid-Refractory Pain in Cancer Patients 
Shekhar Sharma, MS, M.R. Rajagopal, MD, DNB, Gayatri Palat, MD, DNB, Charu Singh, MD, Altaf G. Haji, MS, DNB, Dimpel Jain, DA 
Journal of Pain and Symptom Management 
Volume 37, Issue 1, Pages (January 2009)
DOI: /j.jpainsymman
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Chart depicting individual NAS pain score before each infusion (lidocaine and saline).
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Chart depicting the magnitude of change in pain scores for individual patients after each infusion (lidocaine and saline).
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Chart depicting percent response (groups of 10% increments) after each infusion.
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Chart depicting number of patients showing response (>50% pain relief) after each infusion.
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5 Comparative chart for effect of lidocaine and placebo.
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions

7. Fig. 6
Chart depicting the percent response seen after each infusion in patients grouped by their subjective choice of better infusion.
Journal of Pain and Symptom Management  , 85-93DOI: ( /j.jpainsymman )
Copyright © 2009 U.S. Cancer Pain Relief Committee Terms and Conditions